A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.
Hair regrowth in transfems is more effective due to hormonal changes, specifically estrogen, which keeps hair in growth phase longer. Treatments mentioned include anti-androgens, sex hormones, and DHT blockers like finasteride.
The user has been mixing finasteride with stemoxydine for hair loss and is considering switching to a less expensive product with a different ingredient list. They are questioning if the new product's higher water content compared to alcohol will affect the finasteride's solubility.
The user has been using finasteride and dutasteride for hair loss but is experiencing low energy and motivation, possibly due to high prolactin levels. Despite treatment, hairline recession continues, and the user is considering the impact of low DHT levels on overall health and energy.
Increased hair shedding after 3 months of using 0.25mg finasteride, with thin, tapered hairs falling out. The user is concerned about the sudden change in shedding pattern.
The user is experiencing a second hair shedding phase after 7 months on finasteride, oral minoxidil, and ketoconazole, and is concerned about the sustainability of the treatment. Others encourage continuing the treatment, explaining that shedding is normal and should stabilize over time.
Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.
Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.
A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.
The user has been using Finasteride 1mg daily for over 6 months, experiencing decreased shedding and denser hair, and is considering adding Minoxidil to their regimen. They also addressed a past vitamin D deficiency with supplements and are hopeful for continued hair regrowth.
Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.
The user is experiencing a lack of morning erections after using 0.5mg of finasteride every other day for two weeks and is considering whether to reduce the dose, continue, or stop. The discussion focuses on adjusting finasteride dosage due to side effects.
PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
The post discusses a user's successful hair regrowth using finasteride, dutasteride, topical minoxidil, and estrogen over nine months. The user, who is male-to-female (mtf), reports significant regrowth and no side effects beyond typical hormone replacement therapy effects.
The user experienced a significant drop in libido and erectile issues after increasing their finasteride dosage, combining oral and topical treatments. They plan to take a break and resume using a lower concentration of topical finasteride to manage side effects.
Pyrilutamide, a potentially effective hair loss treatment; other topical treatments like RU58841 and CB-03-01 that may have fewer side effects than Pyrilutamide; and the Phase 3 clinical trials of Pyrilutamide, which is likely to be approved by the FDA soon.
The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.
The user experienced significant hair regrowth using finasteride and minoxidil but developed erectile dysfunction. They are considering stopping finasteride and relying on minoxidil alone to see if the side effects improve.
A user is seeking a pharmacy to compound a topical solution containing Minoxidil, Finasteride, Alfatradiol, Melatonin, Latanoprost, and either RU58841 or Pyrilutamide. They prefer a professional compounding lab over DIY methods.
Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.
A user experienced 12 months of hair shedding on finasteride and is unsure about continuing, increasing the dose, or switching to dutasteride. Suggestions include adding minoxidil, adjusting finasteride dosage, and checking for deficiencies.
A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.
The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
The post expresses frustration over the unavailability of pure topical finasteride in India despite the developed pharma industry. The user seeks advice on making it at home and its effectiveness.
Switching from liquid to foam minoxidil may cause mild shedding, possibly due to differences in absorption. Returning to the original liquid formulation typically stabilizes shedding within a few weeks.
The user has been taking finasteride for nearly two months and has noticed an increased urge to urinate with slight discomfort. They are questioning if this side effect is temporary.